GlaxoSmithKline Capital PLC EMTN Supplementary Prospectus (6533G)
November 26 2020 - 6:38AM
UK Regulatory
TIDMAG99
RNS Number : 6533G
GlaxoSmithKline Capital PLC
26 November 2020
Issued: 26 November 2020, London UK - LSE Announcement
Publication of Supplementary Prospectus
The following base prospectus dated 26 November 2020 has been
approved by the UK Listing Authority and is available for
viewing:
GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GSK Capital
K.K. GBP20,000,000,000 Euro Medium Term Note Programme
Copies of the supplementary prospectus have been submitted to
the UK Listing Authority's National Storage Mechanism submission
portal via the Electronic Submission System. The base prospectus
will shortly be available for inspection at and can be downloaded
from:
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
For further information, please contact:
GlaxoSmithKline plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
Enquiries:
UK Media enquiries: David Mawdsley (020) 8047 5564
Simon Steel (020) 8047 3763
European Analyst/Investor
enquiries: James Dodwell (020) 8047 2406
Danielle Smith (020) 8047 0932
BASIS ON WHICH YOU MAY ACCESS THE SUPPLEMENTARY PROSPECTUS
Please note that the information contained in the base
prospectus may be addressed to and/or targeted at persons who are
residents of particular countries (specified in the base
prospectus) only and is not intended for use and should not be
relied upon by any person outside these countries and/or to whom
the offer contained in the base prospectus is not addressed. Prior
to relying on the information contained in the base prospectus you
must ascertain from the base p rospectus whether or not you are
part of the intended addressees of the information contained
therein.
Your right to access this service is conditional upon complying
with the above
GlaxoSmithKline plc
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PSPPPGQWGUPUGPQ
(END) Dow Jones Newswires
November 26, 2020 07:38 ET (12:38 GMT)
Glaxosmsc 5.25% (LSE:AG99)
Historical Stock Chart
From Oct 2024 to Nov 2024
Glaxosmsc 5.25% (LSE:AG99)
Historical Stock Chart
From Nov 2023 to Nov 2024